Roginolisib
- Generic Name
- Roginolisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27FN4O5S
- CAS Number
- 1305267-37-1
- Unique Ingredient Identifier
- 6K8FC2TF54
- Associated Conditions
- -
- Associated Therapies
- -
iOnctura achieves new clinical milestones in uveal melanoma therapy
iOnctura's phase 1 DIONE-01 study shows roginolisib's clinical activity and safety in uveal melanoma patients, with median overall survival of 16 months, double historical controls. The drug is well-tolerated, with less than 7% experiencing grade 3/4 adverse events. The findings support ongoing phase 2 OCULE-01 study.
iOnctura reaches new clinical milestones in uveal melanoma
The Phase I DIONE-01 study shows roginolisib, an allosteric modulator of PI3Kδ, is well-tolerated and safe, with long-term use up to 4.5 years. In uveal melanoma patients, it doubled overall survival to 16 months compared to historical controls. A Phase II OCULE-01 study is ongoing.
Biotech leader champions targeted cancer treatments and diversity
Dr. Catherine Pickering, CEO of iOnctura, champions targeted cancer treatments and diversity in biotech, focusing on the PI3K pathway and advocating for gender balance in STEM careers.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath